文献速递造血干细胞移植与细胞治疗白血病

ATIR101降低急性白血病单倍体移植非复发死亡并改善总生存

ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia.
PubMed 文献 · Leukemia · 2020-02-11

本研究评估了T细胞清除单倍体HSCT后输注ATIR101(去宿主反应性T细胞、富集初始细胞的单倍体T细胞产品)的安全性和有效性。2期多中心研究中23例急性白血病患者6个月非复发死亡率为13%,1年非复发死亡低于单纯TCD-haplo,无GVHD无复发生存优于MMUD和UCB移植。

要点

  • ATIR101后6个月非复发死亡率为13%
  • 1年非复发死亡低于单纯TCD-haplo(P=0.008)
  • 1年GRFS优于MMUD和UCB移植

核心结论

  • TCD-haplo后输注ATIR101可能消除移植后免疫抑制需求而不增加GVHD风险,GRFS与MUD移植相似。

研究设计与样本

  • 2期多中心研究,23例急性白血病患者接受TCD-haplo+ATIR101,与TCD-haplo alone(n=35)、MUD(n=64)、MMUD(n=37)、UCB(n=22)观察队列比较。

主要发现

  • 6个月非复发死亡率为13%。
  • 1年非复发死亡低于TCD-haplo alone(P=0.008)。
  • 1年GRFS:TCD-haplo+ATIR101为56.5%,MMUD为27.0%,UCB为22.7%(两者P<0.03);与MUD的40.6%无统计学差异。
  • 高第三方反应性的ATIR101移植物与更少的临床相关病毒感染相关。

临床怎么用

  • 急性白血病患者TCD-haplo后输注ATIR101可能作为无移植后免疫抑制的替代策略。

局限性

  • 2期单臂研究,样本量小(23例),与观察队列比较,需随机3期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overcoming graft-versus-host disease (GvHD) without increasing relapse and severe infections is a major challenge after allogeneic hematopoietic stem-cell transplantation (HSCT). ATIR101 is a haploidentical, naïve cell-enriched T-cell product, depleted of recipient-alloreactive T cells to minimize the risk of GvHD and provide graft-versus-infection and -leukemia activity. Safety and efficacy of ATIR101 administered after T-cell-depleted haploidentical HSCT (TCD-haplo + ATIR101) without posttransplant immunosuppressors were evaluated in a Phase 2, multicenter study of 23 patients with acute leukemia and compared with an observational cohort undergoing TCD-haplo alone (n = 35), matched unrelated donor (MUD; n = 64), mismatched unrelated donor (MMUD; n = 37), and umbilical cord blood (UCB; n = 22) HSCT. The primary endpoint, 6-month non-relapse mortality (NRM), was 13% with TCD-haplo + ATIR101. One year post HSCT, TCD-haplo + ATIR101 resulted in lower NRM versus TCD-haplo alone (P = 0.008). GvHD-free, relapse-free survival (GRFS) was higher with TCD-haplo + ATIR101 versus MMUD and UCB (both P < 0.03; 1-year rates: 56.5%, 27.0%, and 22.7%, respectively) and was not statistically different from MUD (1 year: 40.6%). ATIR101 grafts with high third-party reactivity were associated with fewer clinically relevant viral infections. Results suggest that haploidentical, selective donor-cell depletion may eliminate requirements for posttransplant immunosuppressors without increasing GvHD risk, with similar GRFS to MUD. Following these results, a randomized Phase 3 trial versus posttransplant cyclophosphamide had been initiated.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Roy DC, Walker I, Maertens J, et al. ATIR101 administered after T-cell-depleted haploidentical HSCT reduces NRM and improves overall survival in acute leukemia. Leukemia. 2020. PMID: 32047237. doi:10.1038/s41375-020-0733-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。